Crizotinib, an inhibitor of tyrosine receptor kinases, including ALK and CD117, has been found to be effective against inflammatory myofibroblastic tumor or non-small cell lung cancer with ALK rearrangement [6]. This evidence concerns the gene ALK and inflammatory myofibroblastic tumor.